NorthCrest Asset Manangement LLC Grows Stock Holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG)

NorthCrest Asset Manangement LLC boosted its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 1,090.1% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 19,530 shares of the medical equipment provider's stock after buying an additional 17,889 shares during the quarter. NorthCrest Asset Manangement LLC's holdings in Intuitive Surgical were worth $9,673,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Onefund LLC grew its holdings in shares of Intuitive Surgical by 1.9% during the fourth quarter. Onefund LLC now owns 947 shares of the medical equipment provider's stock worth $494,000 after purchasing an additional 18 shares during the last quarter. AlphaCore Capital LLC grew its holdings in shares of Intuitive Surgical by 4.2% during the fourth quarter. AlphaCore Capital LLC now owns 451 shares of the medical equipment provider's stock worth $235,000 after purchasing an additional 18 shares during the last quarter. Parkside Financial Bank & Trust grew its holdings in shares of Intuitive Surgical by 2.6% during the fourth quarter. Parkside Financial Bank & Trust now owns 747 shares of the medical equipment provider's stock worth $390,000 after purchasing an additional 19 shares during the last quarter. Accredited Investors Inc. grew its holdings in shares of Intuitive Surgical by 1.9% during the fourth quarter. Accredited Investors Inc. now owns 1,040 shares of the medical equipment provider's stock worth $543,000 after purchasing an additional 19 shares during the last quarter. Finally, Second Line Capital LLC grew its holdings in shares of Intuitive Surgical by 3.4% during the fourth quarter. Second Line Capital LLC now owns 578 shares of the medical equipment provider's stock worth $302,000 after purchasing an additional 19 shares during the last quarter. Hedge funds and other institutional investors own 83.64% of the company's stock.

Wall Street Analyst Weigh In

ISRG has been the topic of several research reports. Citigroup reaffirmed a "buy" rating and set a $650.00 price objective (up previously from $590.00) on shares of Intuitive Surgical in a report on Thursday, May 22nd. Piper Sandler dropped their price objective on Intuitive Surgical from $670.00 to $575.00 and set an "overweight" rating on the stock in a report on Wednesday, April 23rd. Robert W. Baird decreased their target price on shares of Intuitive Surgical from $600.00 to $575.00 and set an "outperform" rating for the company in a research note on Wednesday, April 23rd. Barclays decreased their target price on shares of Intuitive Surgical from $684.00 to $635.00 and set an "overweight" rating for the company in a research note on Thursday, April 24th. Finally, Truist Financial decreased their target price on shares of Intuitive Surgical from $605.00 to $590.00 and set a "buy" rating for the company in a research note on Wednesday, April 23rd. One analyst has rated the stock with a sell rating, four have assigned a hold rating and fifteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $588.95.

Intuitive Surgical Price Performance

Shares of ISRG stock traded down $0.82 during midday trading on Friday, reaching $512.18. 2,181,892 shares of the company traded hands, compared to its average volume of 1,675,828. The firm's 50 day simple moving average is $526.57 and its two-hundred day simple moving average is $538.46. Intuitive Surgical, Inc. has a 1-year low of $413.82 and a 1-year high of $616.00. The firm has a market cap of $183.57 billion, a PE ratio of 79.90, a price-to-earnings-growth ratio of 5.85 and a beta of 1.67.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last posted its quarterly earnings results on Tuesday, April 22nd. The medical equipment provider reported $1.81 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.71 by $0.10. Intuitive Surgical had a net margin of 27.81% and a return on equity of 14.55%. The company had revenue of $2.25 billion during the quarter, compared to the consensus estimate of $2.19 billion. During the same period last year, the firm earned $1.50 EPS. As a group, research analysts anticipate that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current fiscal year.

Insider Transactions at Intuitive Surgical

In other news, Director Jami K. Nachtsheim sold 2,400 shares of the firm's stock in a transaction that occurred on Thursday, May 1st. The shares were sold at an average price of $520.00, for a total transaction of $1,248,000.00. Following the completion of the transaction, the director now directly owns 6,371 shares of the company's stock, valued at $3,312,920. This trade represents a 27.36% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Gary Loeb sold 1,700 shares of the firm's stock in a transaction that occurred on Friday, April 25th. The stock was sold at an average price of $513.18, for a total transaction of $872,406.00. Following the transaction, the executive vice president now directly owns 2,245 shares of the company's stock, valued at approximately $1,152,089.10. This trade represents a 43.09% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 4,998 shares of company stock valued at $2,611,577 in the last ninety days. Corporate insiders own 0.70% of the company's stock.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.